Trial Profile
A Multicenter and Observational Study to Assess the Effectiveness of Infliximab Comparing With Conventional Therapy in Ankylosing Spondylitis Subjects With Hip Involvement
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Infliximab (Primary) ; Disease-modifying antirheumatics; Nonsteroidal anti-inflammatories
- Indications Ankylosing spondylitis
- Focus Therapeutic Use
- Acronyms RECOVERY
- Sponsors Janssen Research & Development
- 30 Oct 2017 Status changed from active, no longer recruiting to discontinued.
- 13 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 19 Apr 2017 Planned End Date changed from 13 Apr 2018 to 15 Jan 2018.